Inspire Pharmaceuticals

Inspire Pharmaceuticals is a biopharmaceutical company based in Durham, North Carolina. The company employs 245 people and generates $50 million in annual revenue. Inspire Pharmaceuticals focuses on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Their product portfolio includes denufosol tetrasodium for cystic fibrosis, PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, and AZASITE(R) (azithromycin ophthalmic solution) 1% for blepharitis. These products are at various stages of development, with denufosol tetrasodium and PROLACRIA(TM) in Phase 3 and AZASITE(R) in Phase 2. Beyond their internal pipeline, Inspire Pharmaceuticals generates revenue through the promotion of AZASITE(R) for bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis, and royalties from net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Visit Inspire Pharmaceuticals' website at inspire.be for more information.